<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03810144</url>
  </required_header>
  <id_info>
    <org_study_id>128-CL-01</org_study_id>
    <nct_id>NCT03810144</nct_id>
  </id_info>
  <brief_title>Impact of Guided Care With the Vectra DA Multi-biomarker Disease Activity (MBDA) Blood Test</brief_title>
  <acronym>CareFirst</acronym>
  <official_title>Impact of Guided Care With the Vectra DA Multi-biomarker Disease Activity (MBDA) Blood Test on Clinical Outcomes and Pharmaceutical Utilization in Patients With Rheumatoid Arthritis: A Prospective, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myriad Genetic Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myriad Genetic Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nine months multi-center prospective, randomized observational study, two arm trial to
      evaluate the effect of MBDA score-guided care on disease activity and medical costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nine months multi-center prospective, randomized observational study, two arm trial to
      evaluate the effect of MBDA score-guided care on disease activity and medical costs. To
      investigate whether treatment decisions guided by MBDA scores result in reduced disease
      activity and overall medical cost among patients with RA relative to usual care (UC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean MBDA Score</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Change in disease activity from baseline to month 9 as measured by mean MBDA score.
MBDA Score stands for the Vectra DA multi-biomarker disease activity (MBDA) blood test.
Scale: Low (&gt;30); Moderate (30-44); High (&gt;44)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Overall Medical Costs</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>Changes in overall medical costs, RA-related medical costs, pharmacy costs, RA treatment medication costs, and biologic DMARD medication costs from baseline to one year, as defined in Appendix 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Utilization</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>Medical utilization metrics (admissions, readmissions, emergency room visits, physician visits, etc.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients who Showed a Response to Medication</measure>
    <time_frame>Baseline to month 9</time_frame>
    <description>Proportion of patients who showed a response to medication, defined as a decrease in MBDA score of at least 8 from baseline to month 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacy Utilization</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>Pharmacy utilization metrics (days' supply, prescriptions, etc.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Adherence</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>Treatment adherence metrics measured according to medical possession ratio and time to discontinuation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Patients with Non-High MBDA Scores</measure>
    <time_frame>Baseline to month 9</time_frame>
    <description>Proportion of patients with non-high (≤44) MBDA scores from baseline to month 9.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Medical Costs</measure>
    <time_frame>Baseline to 1 year</time_frame>
    <description>Overall medical costs, pharmacy costs, RA treatment medication costs, and biologic DMARD medication costs (Appendix 2) from baseline to one year according to:
Baseline MBDA score category (low &lt;30, moderate 30-44, high &gt;44).
Whether treatment decisions were consistent with the MBDA score-based treatment guidance in Appendix 1 (guided treatment arm only).
Whether MBDA score category changed from baseline to month 9.
Whether biologic DMARD use was tapered.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Vectra Guided</arm_group_label>
    <description>For patients in the guided care arm, treating physicians will receive the Vectra DA MBDA Test score prior to the patient visit and will have a set of guidance for decision-making based on these scores. Treating physicians will be strongly encouraged to follow the guidance but will not be required to do so. For test results to be available at the time of each visit in the MBDA guided treatment arm, blood testing will be performed 7-10 days before the visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <description>For patients in the UC arm, treating physicians will not have access to MBDA scores until the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Vectra DA MBDA Test</intervention_name>
    <description>Vectra Guided versus Usual Care</description>
    <arm_group_label>Vectra Guided</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with RA who are currently taking one or more non-biologic DMARD and/or biologic
        DMARD listed in Appendix 2.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to sign an informed consent form (ICF)

          -  Age at least 18 years old at screening visit

          -  Diagnosed with RA according to 1987 or 2010 criteria of the American College of
             Rheumatology

          -  Actively managed by a CareFirst health care practitioner

          -  Currently taking one or more biologic and/or non-biologic DMARDs listed in Appendix 2

          -  Currently has CareFirst medical coverage

        Exclusion Criteria:

          -  Active infection

          -  History of malignancy within the past 5 years or any evidence of persistent
             malignancy, except fully excised basal cell or squamous cell carcinomas of the skin,
             or cervical carcinoma in situ that has been treated or excised in a curative procedure

          -  Current enrollment in another clinical trial

          -  On non-biologic DMARD monotherapy or combination therapy with stable disease for ≥6
             months

          -  Any condition or circumstance that makes it likely the patient will not be able to
             complete the 9-month trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diana Vogel</last_name>
    <phone>801-746-6532</phone>
    <email>dvogel@myriad.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erica Akins</last_name>
    <phone>5134777732</phone>
    <email>erica.akins@myriad.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Annapolis Rheumatology LLC</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shakeara Collins</last_name>
      <phone>410-897-1941</phone>
      <phone_ext>1119</phone_ext>
      <email>arheumatologyscollins@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Heidi Sami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lifebridge Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Demos</last_name>
      <phone>410-601-5559</phone>
      <email>jademos@lifebridgehealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Harjit (Rosie) Kaur Rahi</last_name>
      <phone>410-601-0960</phone>
      <email>hrahi@lifebridgehealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Emily Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Baltimore LLC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21286</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivy Sandbank</last_name>
      <phone>410-494-1888</phone>
      <phone_ext>106</phone_ext>
      <email>ivy.study@rheumatology-associates.com</email>
    </contact>
    <investigator>
      <last_name>Howard Hauptman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nasseri Clinic of Arthritis &amp; Rheumatic Diseases, LLC.</name>
      <address>
        <city>Catonsville</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samantha Mihm</last_name>
      <phone>410-744-0661</phone>
      <email>smihm@nassericlinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Sahar Nemati</last_name>
      <phone>410-744-0661</phone>
      <email>snemati@nassericlinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nasser Nasseri-Asl, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Care Specialists of Maryland</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Bell, CCMA</last_name>
      <phone>410-992-7440</phone>
      <email>acsmresearch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klein &amp; Associates</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Welsh</last_name>
      <phone>301-724-4337</phone>
      <email>mwelsh@rheumdocs.com</email>
    </contact>
    <investigator>
      <last_name>Steven Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Rheumatology</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Moores</last_name>
      <phone>410-787-9400</phone>
    </contact>
    <investigator>
      <last_name>Erinn Maury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klein &amp; Associates</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Melton</last_name>
      <phone>301-791-6680</phone>
      <phone_ext>1144</phone_ext>
      <email>smelton@rheumdocs.com</email>
    </contact>
    <investigator>
      <last_name>Mary Howell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Klein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashling Bauer, BA</last_name>
      <phone>301-942-6610</phone>
      <email>abauer@arapc.com</email>
    </contact>
    <investigator>
      <last_name>Alan K Matsumoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Herbert SB Baraf, MD, FACP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert L Rosenberg, MD, FACR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evan L Siegel, MD, FACR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole S Thomas, MD, FACR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace E Ahn, MD, FACR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey A Potter, MD, FACR</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grant H Louie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 26, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

